Results 91 to 100 of about 37,289 (232)

Frequency and impact of repeat colonoscopy as a treat‐to‐target approach in pediatric inflammatory bowel disease

JPGN Reports, Volume 7, Issue 1, Page 70-76, February 2026.
Abstract Objectives Endoscopic healing (EH) is a treatment target in inflammatory bowel disease (IBD). However, adherence to repeat colonoscopy (RC) for EH assessment in pediatrics remains variable. We aimed to evaluate the frequency and timing of RC after diagnosis and its impact on treatment decisions at a large pediatric IBD center.
Kari Noel VanEvery, Grace Dukes, Brendan Boyle, Jennifer L. Dotson, Ross M. Maltz, Hilary K. Michel   +5 more
wiley   +1 more source

Early Toxicity in Childhood Acute Lymphoblastic Leukemia: A Comparison of NOPHO ALL2008 and ALLTogether Protocols in Sweden

Pediatric Blood &Cancer, Volume 73, Issue 2, February 2026.
ABSTRACT Background The European ALLTogether protocol for childhood acute lymphoblastic leukemia, initiated in Sweden 2019, introduced earlier asparaginase during induction, dexamethasone instead of prednisone for all patients, and omitted anthracyclines from low‐risk induction to reduce treatment‐related toxicity.
Johannes Fermér, Hannah van Bunningen, Otto Zhou, Jonas Abrahamsson, Magnus Borssen, Isabella Donnér, Mats Heyman, Anna Sällfors Holmqvist, Anders Valind, Hartmut Vogt, Susanna Ranta, Arja Harila   +11 more
wiley   +1 more source

Frequency of Use and Standards of Care for the Use of Azathioprine and 6-Mercaptopurine in Treatment of Inflammatory Bowel Disease: A Systematic Review of the Literature and a Survey of Canadian Gastroenterologists

Canadian Journal of Gastroenterology, 2001
OBJECTIVE: To identify the frequency of use and appropriate monitoring guidelines for the adverse effects of azathioprine and 6-mercaptopurine (6-MP) in the therapy of patients with inflammatory bowel disease (IBD).
Thomas M Wallace, Sander JO Veldhuyzen van Zanten   +1 more
doaj   +1 more source

Clinical and Economic Impact of Expanded TPMT Testing to Prevent Thiopurine‐Induced Myelosuppression in Australia: A Budget Impact Analysis

Clinical and Translational Science, Volume 19, Issue 2, February 2026.
ABSTRACT Testing thiopurine methyltransferase (TPMT) enzyme activity or genotype prior to thiopurine prescribing is recommended to reduce the risk of moderate to severe—and potentially fatal—myelosuppression in poor or intermediate TPMT metabolizers. Despite this, only about one‐third of individuals prescribed thiopurines in Australia currently receive
Bella D. Ianni, Mohammad Afshar Ali, Chin Hang Yiu, Edwin C. K. Tan, Christine Y. Lu   +4 more
wiley   +1 more source

Clinical pharmacists’ knowledge, attitude, perception, and beliefs about the role of pharmacogenetic testing for genes polymorphisms when prescribing mercaptopurine

Saudi Pharmaceutical Journal
Background: Single nucleotide polymorphisms in the gene encoding proteins involved in mercaptopurine metabolism can influence drug efficacy and safety. This study aims to assess clinical pharmacists’ knowledge about mercaptopurine-related genes and their
Norah O. Abanmy, Sara A. Alghamdi, Raneem K. Aljudaie, Omar A. Almohammed   +3 more
doaj   +1 more source

Toxicity of azathioprine: why and when? analysis of the prevalence of polymorphism in Joinville, SC, Brazil

Arquivos de Gastroenterologia, 2012
CONTEXT: The use of thiopurine drugs such as azathioprine and 6-mercaptopurine has become quite common in the treatment of inflammatory bowel disease, transplantation and acute leukemias.
Gabriela Roncone Gastal, Simone Moreira, Caroline Furtado Noble, Leslie Ecker Ferreira, Paulo Henrique Condeixa de França, Mauro Pinho   +5 more
doaj   +1 more source

Antiviral Potential of Azathioprine and Its Derivative 6- Mercaptopurine: A Narrative Literature Review

Pharmaceuticals
The use of azathioprine (AZA) in human medicine dates back to research conducted in 1975 that led to the development of several drugs, including 6-mercaptopurine.
Carolina Rios-Usuga, Marlen Martinez-Gutierrez, Julian Ruiz-Saenz   +2 more
doaj   +1 more source

Mercaptopurine/Methotrexate Maintenance Therapy of Childhood Acute Lymphoblastic Leukemia: Clinical Facts and Fiction

Journal of pediatric hematology/oncology, 2014
The antileukemic mechanisms of 6-mercaptopurine (6MP) and methotrexate (MTX) maintenance therapy are poorly understood, but the benefits of several years of myelosuppressive maintenance therapy for acute lymphoblastic leukemia are well proven. Currently,
K. Schmiegelow, S. N. Nielsen, T. Frandsen, J. Nersting   +3 more
semanticscholar   +1 more source

Allopurinol reverses mercaptopurine-induced hypoglycemia in patients with acute lymphoblastic leukemia [version 1; referees: 2 approved]

F1000Research, 2019
Fasting hypoglycemia is a known complication of mercaptopurine (6MP) maintenance therapy for acute lymphoblastic leukemia (ALL). It is associated with high levels of the methylated metabolite 6-methyl-mercaptopurine (6MMP).
Melissa Zhang, Bruce Bostrom
doaj   +1 more source

Comparative risk of serious infection among biologic therapies for inflammatory bowel disease in pediatric patients: A target trial emulation

Journal of Pediatric Gastroenterology and Nutrition, Volume 82, Issue 2, Page 503-507, February 2026.
Serena Yun‐Chen Tsai, Ashwin N. Ananthakrishnan, Harland S. Winter, Kevin Sheng‐Kai Ma   +3 more
wiley   +1 more source